UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 371

Sortiert nach

AB1014 Effects of teriparatide on bone metabolism of patients with rheumatoid arthritis and osteoarthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.696-696

Kida, D.

2013

Volltextzugriff (PDF)

Effect of tapering glucocorticoids for bone metabolism in patients with rheumatoid arthritis taking tocilizumab

Bone (New York, N.Y.), 2011-05, Vol.48, p.S262-S262

Kida, D

2011

Volltextzugriff (PDF)

AB0514 Extended drug interval trial to clarify the efficacy of tocilizumab after stable status in patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.667-667

2013

Volltextzugriff (PDF)

FRI0217 Extended drug interval trial to clarify the efficacy of tocilizumab after stable status in

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A446-A447

2013

Volltextzugriff (PDF)

SAT0177 The Combination of Serum Matrix Metalloproteinase-3 and C-Reactive Protein at 4 Weeks Predict High Continuation Rate in RA Patients with Adalimumab Therapy

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.718-718

2015

Volltextzugriff (PDF)

FRI0098 The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Interstitial Lung Disease: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.455-455

2015

Volltextzugriff (PDF)

FRI0320 Pregnancy Outcomes in Rheumatoid Arthritis Patients Treated with Tocilizumab

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.501-502

2014

Volltextzugriff (PDF)

AB0246 Study of the Antibody Titer by Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents -Examination of Multiple Dose

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.885-885

2014

Volltextzugriff (PDF)

FRI0141 Retention Rate and Discontinuation Due to Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis Receiving Adalimumab Therapy: A Multicenter Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.472-473

2015

Volltextzugriff (PDF)

FRI0142 Efficacy of the Initial Treatment with Certolizumab Pegol for Rheumatoid Arthritis: A Multicenter Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.473-473

2015

Volltextzugriff (PDF)

AB0480 Clinical Efficacy of TNF Inhibitors and Abatacept in Japanese Rheumatoid Arthritis Patients Switching from Tocilizumab

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1057-1058

2015

Volltextzugriff (PDF)

FRI0237 Study of the antibody titer by influenza vaccination in rheumatoid arthritis patients treated with biological agents

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A453-A454

2013

Volltextzugriff (PDF)

AB0591 Analysis of rheumatoid arthritis patients who were treated with abatacept with rapid effectiveness from japanese multicenter registry system of biological therapy

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.672-672

2013

Volltextzugriff (PDF)

AB0534 Efficacy and safety to use halfdose abatacept therapy between 24weeks in patients with rheumatoid arthritis in japanese

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.668-668

2013

Volltextzugriff (PDF)

AB0515 Predictors of clinical remission (DAS28CRP<2.6) in patients with RA who were treated with abatacept

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.667-667

2013

Volltextzugriff (PDF)

AB0339 A retrospective study on rapidness of efficacy in abatacept terapy in patients with rheumatoid arthritis from japanese multicenter registry system

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A891-A891

2013

Volltextzugriff (PDF)

FRI0286 Clinical Significance of Serum Matrix Metalloproteinase-3 Normalisation in Rheumatoid Arthritis Patients with Anti-TNF Therapy

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.487-488

2014

Volltextzugriff (PDF)

SAT0237 The Clinical Efficacy and Safety of Abatacept for Rheumatoid Arthritis from Japanese Multi-Center Registry: 2-Year Outcomes

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.677-677

2014

Volltextzugriff (PDF)

FRI0287 High Rate of Improvement in Serum Matrix Metalloproteinase-3 Levels at 4 Weeks PREDICT Remission at 52 Weeks in RA Patients with Anti-TNF Therapy

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.488-489

2014

Volltextzugriff (PDF)

SAT0262 Comparison of Serum Matrix Metalloproteinase-3 Levels in Rheumatoid Arthritis after Treatment with Biologic Agents for 24 Weeks

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.688-688

2014

Volltextzugriff (PDF)

AB0365 Prevalence and Factors Associated with Depression and Anxiety in Patients with Rheumatoid Arthritis Using Data from a Large Japanese Cohort Database in 2013 (Ninja 2013 Database)

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1015-1015

2015

Volltextzugriff (PDF)

SAT0093 Pregnancy in patients with rheumatoid arthritis treated witn biological agents: Results of the 8-year of japanese tbc registry

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.501-501

2013

Volltextzugriff (PDF)

AB0485 Predictive Factors for Achievement of Low Disease Activity or Remission at 52 Weeks in Switching from TNF Inhibitors to Abatacept with Background of low Dose or no Methotrexate: A Multicenter Observational Cohort Study in Japan

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1059-1060

2015

Volltextzugriff (PDF)

THU0115 Importance of Both Disease Activity at 12 Weeks and Clinical Response up to 12 Weeks to Predict Achievement of Low Disease Activity at 52 Weeks During Abatacept Treatment in Biologics-Switching Patients with Rheumatoid Arthritis: A Multicenter Observational Cohort Study in Japan

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.235-236

2015

Volltextzugriff (PDF)

Local Political Participation in Japan: A Case Study of Oita

Daigle Kida, Dani

1st, 2019

Volltextzugriff (PDF)

1 – 25 von 371

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(329)
Mit Volltextzugriff
(342)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

AB1014 Effects of teriparatide on bone metabolism of patients with rheumatoid arthritis and osteoarthritis

Effect of tapering glucocorticoids for bone metabolism in patients with rheumatoid arthritis taking tocilizumab

AB0514 Extended drug interval trial to clarify the efficacy of tocilizumab after stable status in patients with rheumatoid arthritis

FRI0217 Extended drug interval trial to clarify the efficacy of tocilizumab after stable status in

SAT0177 The Combination of Serum Matrix Metalloproteinase-3 and C-Reactive Protein at 4 Weeks Predict High Continuation Rate in RA Patients with Adalimumab Therapy

FRI0098 The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Interstitial Lung Disease: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study

FRI0320 Pregnancy Outcomes in Rheumatoid Arthritis Patients Treated with Tocilizumab

AB0246 Study of the Antibody Titer by Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents -Examination of Multiple Dose

FRI0141 Retention Rate and Discontinuation Due to Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis Receiving Adalimumab Therapy: A Multicenter Study

FRI0142 Efficacy of the Initial Treatment with Certolizumab Pegol for Rheumatoid Arthritis: A Multicenter Study

AB0480 Clinical Efficacy of TNF Inhibitors and Abatacept in Japanese Rheumatoid Arthritis Patients Switching from Tocilizumab

FRI0237 Study of the antibody titer by influenza vaccination in rheumatoid arthritis patients treated with biological agents

AB0591 Analysis of rheumatoid arthritis patients who were treated with abatacept with rapid effectiveness from japanese multicenter registry system of biological therapy

AB0534 Efficacy and safety to use halfdose abatacept therapy between 24weeks in patients with rheumatoid arthritis in japanese

AB0515 Predictors of clinical remission (DAS28CRP<2.6) in patients with RA who were treated with abatacept

AB0339 A retrospective study on rapidness of efficacy in abatacept terapy in patients with rheumatoid arthritis from japanese multicenter registry system

FRI0286 Clinical Significance of Serum Matrix Metalloproteinase-3 Normalisation in Rheumatoid Arthritis Patients with Anti-TNF Therapy

SAT0237 The Clinical Efficacy and Safety of Abatacept for Rheumatoid Arthritis from Japanese Multi-Center Registry: 2-Year Outcomes

FRI0287 High Rate of Improvement in Serum Matrix Metalloproteinase-3 Levels at 4 Weeks PREDICT Remission at 52 Weeks in RA Patients with Anti-TNF Therapy

SAT0262 Comparison of Serum Matrix Metalloproteinase-3 Levels in Rheumatoid Arthritis after Treatment with Biologic Agents for 24 Weeks

AB0365 Prevalence and Factors Associated with Depression and Anxiety in Patients with Rheumatoid Arthritis Using Data from a Large Japanese Cohort Database in 2013 (Ninja 2013 Database)

SAT0093 Pregnancy in patients with rheumatoid arthritis treated witn biological agents: Results of the 8-year of japanese tbc registry

AB0485 Predictive Factors for Achievement of Low Disease Activity or Remission at 52 Weeks in Switching from TNF Inhibitors to Abatacept with Background of low Dose or no Methotrexate: A Multicenter Observational Cohort Study in Japan

THU0115 Importance of Both Disease Activity at 12 Weeks and Clinical Response up to 12 Weeks to Predict Achievement of Low Disease Activity at 52 Weeks During Abatacept Treatment in Biologics-Switching Patients with Rheumatoid Arthritis: A Multicenter Observational Cohort Study in Japan

Local Political Participation in Japan: A Case Study of Oita

Suchergebnisse filtern